Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pathology

Background: Breast cancer is a highly diverse disease that can be classified into subtypes comprising different clinical or cellular characteristics. It is commonly subclassified into five subtypes: luminal A, luminal B, luminal HER2/neu, HER2/neu enriched and triple negative breast cancer (TNBC) (Asano et al., 2017). Several studies have reported conflicting results regarding the impact of subtype on the probability of nodal metastasis, and even those studies showing a correlation disagree over which subtypes carry the greatest risk (Jones et al., 2013). Regarding neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS) (Esserman et al., 2012). Material and methods: To determine breast cancer subtypes, we characterized 78 tumor biopsies and their specimens obtained from National Cancer Institute, Cairo university by reevaluating ER, PR, HER2/neu, and Ki-67 immunohistochemistry together with re-examination of Hx and E stained slides for both biopsies and specimens to reach histopathological diagnoses, tumour grades, histopathological criteria and postneoadjuvant chemotherapy response. Retrieval of patients{u2019} files was done for clinical data and correlation with disease free survival (DFS) was done

Issued also as CD